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Trends in type 2 diabetes mellitus 
disease burden in European Union 
countries between 1990 and 2019
Richard Goodall 1,2,3,9*, Andrew Alazawi 3,4,9, Will Hughes 3,5, Vassiliki Bravis 6, 
Justin D. Salciccioli 3,7, Dominic C. Marshall3,6, Conor Crowley 3,8 & Joseph Shalhoub 3,6
This observational study aimed to assess trends in type 2 diabetes mellitus (T2DM) disease burden in 
European Union countries for the years 1990–2019. Sex specific T2DM age-standardised prevalence 
(ASPRs), mortality (ASMRs) and disability-adjusted life-year rates (DALYs) per 100,000 population 
were extracted from the Global Burden of Disease (GBD) Study online results tool for each EU country 
(inclusive of the United Kingdom), for the years 1990–2019. Trends were analysed using Joinpoint 
regression analysis. Between 1990 and 2019, increases in T2DM ASPRs were observed for all EU 
countries. The highest relative increases in ASPRs were observed in Luxembourg (males + 269.1%, 
females + 219.2%), Ireland (males + 191.9%, females + 165.7%) and the UK (males + 128.6%, 
females + 114.6%). Mortality trends were less uniform across EU countries, however a general trend 
towards reducing T2DM mortality was observed, with ASMRs decreasing over the 30-year period 
studied in 16/28 countries for males and in 24/28 countries for females. The UK observed the highest 
relative decrease in ASMRs for males (− 46.9%). For females, the largest relative decrease in ASMRs 
was in Cyprus (− 67.6%). DALYs increased in 25/28 countries for males and in 17/28 countries for 
females between 1990 and 2019. DALYs were higher in males than females in all EU countries in 2019. 
T2DM prevalence rates have increased across EU countries over the last 30 years. Mortality from T2DM 
has generally decreased in EU countries, however trends were more variable than those observed for 
prevalence. Primary prevention strategies should continue to be a focus for preventing T2DM in at risk 
groups in EU countries.
In 2019, the global estimate for the number of adults over 18 years of age with diabetes mellitus was 451  million1, 
with an estimated 5 million worldwide deaths attributable to diabetes among people aged 20–99  years1. Treating 
diabetes and its complications cost the National Health Service (NHS) in the United Kingdom (UK) an estimated 
£14 billion in  20182, representing 10% of the annual NHS budget for England and Wales. Causal associations 
exist between obesity, unhealthy diet, physical inactivity and type 2 diabetes mellitus (T2DM)1. Comparisons of 
up to date prevalence and mortality outcomes from T2DM across European countries are lacking.
The principal aim of this study was to compare the trends in prevalence and mortality from T2DM in the 
countries of the European Union (EU) (inclusive of the United Kingdom). The study aimed to further assess the 
differential burden of disease across EU countries using disability-adjusted life-years (DALYs). We carried out 
an observational analysis of the Global Burden of Disease (GBD)  database3,4 to assess prevalence, mortality and 
disability-adjusted life-years from T2DM in the EU countries between 1990 and 2019.
Online methods
Characteristics of the data source. The data for this observational analysis of T2DM was obtained from 
the GBD database, which amalgamates datasets from 127 countries to provide mortality and disability data 
(deaths, death rates, years of life lost due to premature mortality, prevalence and incidence) for a collection of 
the world’s most important health concerns, as commissioned by the World Health Organisation (WHO). The 
exact GBD methodology has been published  previously3,4, and we have previously described this methodol-
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ogy in observational analyses of trends in the disease burden of peripheral arterial  disease5, abdominal aortic 
 aneurysm6, and lower extremity  amputation7.
The GBD Study defines T2DM as a fasting plasma glucose (FPG) ≥ 7  mmol/L (126  mg/dL), or 
HbA1c > 48 mmol/mol (6.5%), or those currently treated with anti-hyperglycaemic drugs or  insulin3,4. The 
GBD uses different data sources and models to estimate mortality, prevalence and DALY rates, for which detailed 
descriptions are  available3,4.
Briefly, for estimates of disease mortality, the GBD Study assigns each death to its single underlying cause, i.e. 
the cause that initiated the series of events that lead to death. For the present analysis, T2DM-related deaths in 
the total population, listed as the underlying cause of death, is defined as International Classification of Diseases-
Tenth Edition (ICD-10) code E11. ICD-10 codes for T1DM were excluded. GBD mortality data is registered into 
a causes of death database, combining mortality estimates derived from multiple different types of data source 
(including vital registration (VR), verbal autopsy (VA), cancer registry, police records, sibling history, surveil-
lance, and survey/census). VR data obtained from the WHO mortality database represent the source for most 
cause-of-death data, and individual countries submit a compilation of data to the WHO each year. Further VR 
data are identified and obtained from country-specific mortality databases operated by official offices. Unspecified 
diabetes deaths are redistributed on the basis of regression, in which the true proportions of type 1 and type 2 
deaths by age-sex-location-year are a function of the proportion of unspecified deaths, age, the age-standardised 
prevalence of obesity and an interaction term for age and obesity prevalence.
A further component of the GBD methodology for cause of death estimates includes identification and 
redistribution of deaths assigned to ICD codes that either: cannot be the underlying cause of death (e.g. senility 
or frailty); are an intermediate cause of death rather than the underlying cause (e.g. sepsis and heart failure); 
or lack specificity in coding (e.g. diabetes (type not specified) or unspecified cardiovascular disease). These are 
described by the GBD authors as garbage codes, and are re-distributed to a single underlying cause of death 
using a garbage code redistribution algorithm described by Naghavi et al.8.
To characterise the quality of the mortality data available in each country, the GBD authors grade the reli-
ability of annual cause of death estimates on a 5-star scale. For the countries analysed in the present analysis, 
with the exceptions of Cyprus and Slovakia (2-stars and 3-stars, respectively), 15 EU countries scored 4-stars 
(Belgium, Bulgaria, Croatia, Czech Republic, Denmark, France, Germany, Greece, Luxembourg, Netherlands, 
Poland, Portugal, Romania, Slovenia and Spain), representing greater than 65% completeness of mortality data. 
The UK and the 10 remaining EU countries have 5-star data, demonstrating greater than 85% completeness of 
the data (Austria, Estonia, Finland, Hungary, Ireland, Italy, Latvia, Lithuania, Malta and Sweden).
For estimations of disease prevalence, the GBD uses systematic reviews, survey data, disease registries, hospi-
tal administrative data, claims, inpatient and outpatient data, and case notifications as data sources. Using these 
data as input, population prevalence estimates (with corresponding confidence intervals) are computed using 
the DisMod-MR 2.1 meta-regression tool. Multiple cross-walks were performed on the available data-sets prior 
to the analysis to establish a standard reference definition; fasting plasma glucose > 126 mg/dL/7 mmol/L, or 
HbA1c > 48 mmol/mol (6.5%), or being on relevant treatment.
DALYs are calculated by the GBD group as the sum of years of life lost (YLL) and years lived with disability 
(YLD). GBD methodology computes YLL by multiplying the standard life-expectancy at the age of death by the 
estimated number of deaths (per cause)9. YLD were calculated by multiplying the prevalence of T2DM by the 
disability weighting for T2DM (gathered from the GBD 2013 European disability weights measurement study)13. 
YLDs are then corrected for co-morbidities via a microsimulation process, before combining with YLLs to give 
estimated DALYs and their corresponding uncertainty estimates.
The produced information is available to the public and can be extracted via the GBD Results Tool (http:// 
ghdx. healt hdata. org/ gbd- resul ts- tool). We used this tool to extract age-standardised prevalence, mortality and 
DALY rates for diabetes mellitus for EU countries and the UK between 1990 and 2019.
Handling of the GBD data. Age-standardised prevalence rates (ASPRs), age-standardised mortality rates 
(ASMRs) and DALYs per sex per 100,000 population for T2DM were extracted from the GBD Results Tool for 
each of the years between 1990 and 2019, inclusive, for the UK and EU countries. Extracting age-standardised 
rates improves inter-country comparability, because differences in the age-structure of different populations 
are accounted for. For all age-standardised rates, the GBD Study computes a standard population using a non-
weighted average across a percentage of the population of all countries in each five-year age bracket (years 2010–
2035) from the United Nations Population Division’s World Population Prospects (2012 revision)9,10. Absolute 
and relative changes in ASPRs, ASMRs and DALYs over the observation period (i.e. differences between the 
rates in 1990 and 2019) were calculated for each sex in each country.
Statistical analysis. Joinpoint regression analysis was used to assess trends in the disease burden of T2DM. 
The Joinpoint software (Joinpoint Command Line Version 4.5.0.1) was provided by the United States National 
Cancer Institute Surveillance Research  Program11. This software tracks trends in data over time (for the present 
analysis, ASPRs, ASMRs and DALYs), then fits the simplest model possible to the data by connecting several 
different line segments on a logarithmic scale. These segments are known as ‘Joinpoints’, with the simplest model 
(i.e. 0 Joinpoints) being a straight line. As more Joinpoints are added, each is tested for significance using a 
Monte Carlo permutation method. The software also gives estimated annual percent changes (EAPC) for each 
line segment (with corresponding 95% confidence intervals). Each EAPC is tested to establish if a difference 
from the null hypothesis of no change exists. Consequently, the final model consists of multiple Joinpoints, each 
representing a statistically significant (p value < 0.05) change in trend (increase or decrease), with each trend 
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described by the EAPC and the associated 95% confidence intervals. The EAPC allows assessment of trend 
changes at a constant percent per year.
Results
Over the 30-year period studied, changes were observed in T2DM mortality, prevalence and DALYs across the 
28 EU countries.
2019 T2DM mortality. Data for the 2019 T2DM ASMRs per 100,000 for males and females in the 28 
EU countries are demonstrated in Fig. 1. In 2019, the highest ASMRs were observed in Cyprus for both males 
and females (28.1 and 25.0/100,000, respectively). The lowest ASMRs were observed in Finland for both males 
and females (4.2 and 2.6/100,000, respectively). The 2019 ASMRs were higher in males than females in all 28 
included countries. In the UK in 2019, the ASMR was 5.0/100,000 for males and 3.7/100,000 for females, which 
represented the third lowest ASMRs (for both sexes) of all included countries.
2019 T2DM prevalence. Figure 1 demonstrates ASPRs per 100,000 per country in 2019 for males and 
females, respectively. The highest ASPRs in 2019 were observed in the Czech Republic and United Kingdom 
for males (10,198.2 and 9,120.5/100,000, respectively) and females (7270.2 and 6806.3/100,000, respectively). 
France had the lowest ASPR in 2019 for males (2714.4/100,000) and females (2283.3/100,000). The 2019 ASPR 
was higher in males than females in all 28 countries.
2019 T2DM disability-adjusted life-years. Figure  1 shows the 2019 DALYs per 100,000 population 
for all 28 countries studied. The highest 2019 DALYs for both sexes were observed in the Czech Republic 
(1190.5/100,000 for males, 859.5/100,000 for females). The lowest 2019 DALYs were observed in both sexes 
in France (332.3/100,000 for males, 231.7/100,000 for females). In 2019, Male DALYs were higher than female 
DALYs in all 28 countries.
Trends in T2DM mortality. Male ASMRs decreased in 16 of the 28 countries over the 30-year study period. 
For females, ASMRs decreased in 24 countries. The largest relative increases in ASMR between 1990 and 2019 in 
males and females were observed in Latvia (+ 82.5% for males, + 55.1% for females). The largest relative decrease 
in ASMR for males from 1990 to 2019 was in the UK (-46.9%). In females, the largest relative decreases in ASMR 
was identified in Cyprus (−67.6%). Females in the UK observed a −47.1% reduction in ASMRs over the period. 
This data can be found in Supplementary Tables 1a and 1b.
Trends in T2DM prevalence. The overall trend between 1990 and 2019 for T2DM ASPRs in males and 
females increased in all 27 EU countries and the UK. These percentage change data are displayed in Supplemen-
tary Tables 1a and 1b. The largest increases in T2DM ASPR between 1990 and 2019 were observed in Luxem-
bourg, Ireland and the UK for both males and females. (Luxembourg: males + 269.1%, females + 219.2%; Ireland: 
males + 191.9%, females + 165.7%; UK: males + 128.6%, females + 114.6%).
Trends in T2DM disability-adjusted life years. Relative reductions in DALYs were observed in 3 of 
28 countries for males (Cyprus, Malta and the Netherlands), and 11 of 28 countries for females. The greatest 
relative increase in DALYs was observed in Luxembourg for males (+ 99.3%), and the UK for females (+ 35.9%). 
The largest relative reduction in DALYs was observed in Cyprus for both sexes (− 26.2% for males, − 31.2% for 
females). Data are presented in Supplementary Tables 1a and 1b.
Joinpoint analysis for T2DM mortality. Sex-specific Joinpoint regression analyses for T2DM ASMRs 
between 1990 and 2019 are displayed in Fig. 2, and Tables 1 and 2. Significant ASMR estimated annual percent-
age changes (EAPCs) for each trend are presented (p value < 0.05). Trends in ASMRs varied both between and 
within countries. The single greatest increase in ASMR was observed in Slovenia for both sexes (EAPC + 14.4% 
for males between 1990 and 1994 and + 7.6% for females between 1990 and 1996). Slovenia also reported the 
single greatest reductions in ASMRs in both sexes (EAPC − 11.1% for males between 2003 and 2009 and − 12.2% 
for females between 2002 and 2009). No country observed persistently positive trends, for either sex. Persistently 
negative Joinpoint trends between 1990 and 2019 in ASMR were observed in Finland, Italy, Luxembourg and 
Spain for males, and in Cyprus, Ireland, Luxembourg, Malta and Spain for females. For both sexes, data for the 
UK demonstrates significant decreases in ASMR EAPCs from 1990 to 2011, followed by a plateau to insignificant 
EAPCs observed until 2019.
Joinpoint analysis for T2DM prevalence. Sex-specific Joinpoint regression analyses for T2DM ASPRs 
between 1990 and 2019 are displayed in Fig. 3, and Tables 3 and 4. Significant ASPR EAPCs are presented (p 
value < 0.05). Increasing trends in T2DM prevalence were observed in all countries for both sexes. The rate of 
increase in ASPR varied across and within countries. Consistent, significantly positive trends were observed 
in 12 of the 28 countries in males, and in 11 countries in females. Over the time period studied, the most 
rapidly increasing ASPRs in males were observed in Poland (2005–2010 EAPC + 6%), Hungary (2017–2019 
EAPC + 6%) and Luxembourg (2000–2010 EAPC + 6%). For females, the most rapidly increasing ASPRs for 
T2DM were observed between 2017 and 2019 in Ireland (EAPC + 6.8%) and Luxembourg (EAPC + 8.8%). The 
UK observed consistent, significantly positive increases in T2DM ASPRs from 1996/7–2015 for both males and 
females (EAPC increases of + 3.2% to + 5.0%), followed by a plateau from 2015, where non-significant EAPCs of 
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Figure 1.  2019 T2DM disease burden. 2019 age-standardised mortality rates (ASMRs) (A&B), age-
standardised prevalence rates (ASPRs) (C&D) and disability-adjusted life years (DALYs) (E&F) per 100,000 
population for type 2 diabetes mellitus (T2DM) in all EU countries and the UK.
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Figure 2.  Trends in T2DM mortality. Trends in age-standardised death rates (ASDRs) per 100,000 population 
resulting directly from type 2 diabetes mellitus (T2DM) in all European Union (EU) countries and the UK from 
1990 to 2019. Open squares represent males, filled circles represent females.
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Table 1.  Joinpoint analysis for age-standardised mortality rates (ASMRs) per 100,000 population resulting 
directly from type 2 diabetes mellitus (T2DM) in males. Italic values indicates 95% confidence intervals. 
EAPC indicates estimated annual percentage change with 95% confidence intervals in brackets. *Significantly 
different from 0 (P < 0.05).
Trend 1 Trend 2 Trend 3 Trend 4
Years EAPC Years EAPC Years EAPC Years EAPC
Austria 1990–2000 − 0.4*(−0.7 to − 0.1) 2000–2005
 + 9.5*
(+ 8.3 
to  + 10.8)
2005–2011 −3.9*(− 4.6 to − 3.1) 2011–2019
−1.2*
(−1.6 to−0.8)
Belgium 1990–1999  + 0.4*(+ 0.1 to + 0.8) 1999–2009
−1.7*
(−2.0 to− 1.4) 2009–2016
−2.7*
(−3.3 to − 2.1) 2016–2019
 + 1.0
(− 0.8 to + 2.9)
Bulgaria 1990–1996  + 4.8*(+ 4.0 to + 5.7) 1996–2007
−0.9*
(− 1.3 to − 0.6) 2007–2013
− 3.8*
(− 4.9 to − 2.8) 2013–2019
 + 1.7*
(+ 0.9 to + 2.5)
Croatia 1990–1997  + 4.2*(+ 3.3 to + 5.1) 1997–2001
− 3.9*
(− 7.1 to − 0.6) 2001–2007
 + 1.3
(− 0.2 to + 2.8) 2007–2019
− 1.1*
(− 1.5 to − 0.7)
Cyprus 1990–1993
 + 7.3*
(+ 3.5 to 
+ 11.3)
1993–2010 − 1.9*(− 2.2 to − 1.7) 2010–2019
− 5.8*




(− 10.8 to 
− 9.1)
1996–2005  + 3.4*(+ 2.8 to + 4.0) 2005–2015
 + 7.1*
(+ 6.5 to + 7.6) 2015–2019
− 1.5
(− 3.2 to + 0.2)
Denmark 1990–1996  + 1.3*(+ 0.3 to + 2.4) 1996–1999
 + 8.5*
(+ 2.2 to 
+ 15.1)
1999–2003  + 4.7*(+ 1.7 to + 7.9) 2003–2019
− 1.9*
(− 2.1 to − 1.7)
Estonia 1990–1999  + 2.4*(+ 1.0 to + 3.9) 1999–2007
 + 7.0*
(+ 4.8 to + 9.3) 2007–2010
− 10.9
(− 23.7 to 
+ 4.1)
2010–2019 − 1.5*(− 2.9 to − 0.1)
Finland 1990–2002 − 0.9*(− 1.1 to − 0.7) 2002–2012
− 2.4*
(− 2.7 to − 2.1) 2012–2019
− 0.1
(− 0.6 to + 0.4)
France 1990–1995  + 0.4(− 0.4 to + 1.3) 1995–2002
 + 6.4*
(+ 5.7 to + 7.0) 2002–2016
− 2.7*
(− 2.9 to − 2.5) 2016–2019
0.0
(− 1.8 to + 1.9)
Germany 1990–1995  + 2.9*(+ 2.0 to + 3.8) 1995–1999
− 4.9*
(− 6.7 to − 3.0) 1999–2007
− 2.2*
(− 2.7 to − 1.6) 2007–2019
− 0.2
(− 0.4 to 0.0)
Greece 1990–1998 − 4.4*(− 5.0 to − 3.9) 1998–2001
 + 2.1
(− 2.8 to + 7.2) 2001–2007
 + 4.3*
(+ 3.1 to + 5.4) 2007–2019
− 0.9*
(− 1.2 to − 0.7)
Hungary 1990–2000  + 1.3*(+ 0.7 to + 1.9) 2000–2006
 + 6.2*
(+ 4.3 to + 8.1) 2006–2013
− 2.8*
(− 4.1 to − 1.5) 2013–2019
 + 0.9
(− 0.4 to + 2.3)
Ireland 1990–1993  + 2.1(− 0.4 to + 4.6) 1993–2006
− 0.8*
(− 1.1 to − 0.5) 2006–2014
− 3.7*
(− 4.3 to − 3.1) 2014–2019
− 0.7
(− 1.8 to + 0.5)
Italy 1990–2009 − 0.6*(− 0.7 to − 0.5) 2009–2019
− 1.1*
(− 1.4 to − 0.9)
Latvia 1990–1994
 + 12.2*
(+ 6.7 to 
+ 17.9)
1994–2000 − 3.0(− 6.3 to + 0.5) 2000–2010
 + 5.5*
(+ 4.0 to + 7.0) 2010–2019
− 1.8*
(− 3.2 to − 0.4)
Lithuania 1990–1994
 + 6.9*
(+ 3.3 to 
+ 10.5)
1994–1999 − 4.6*(− 7.8 to − 1.4) 1999–2006
 + 3.8*
(+ 2.0 to + 5.7) 2006–2019
− 0.5
(− 1.0 to + 0.1
Luxembourg 1990–2005 − 0.7*(− 0.9 to − 0.5) 2005–2013
− 2.3*
(− 2.9 to − 1.8) 2013–2016
− 4.2*
(− 8.0 to − 0.3) 2016–2019
− 0.3
(− 2.3 to + 1.7)
Malta 1990–1996 − 3.7*(− 4.9 to − 2.5) 1996–2005
 + 0.8
(0.0 to + 1.6) 2005–2019
− 2.3*
(− 2.6 to − 1.9)
Netherlands 1990–1997 − 1.6*(− 2.0 to − 1.2) 1997–2003
 + 2.3*
(+ 1.6 to + 3.0) 2003–2013
− 5.7*
(− 6.0 to − 5.5) 2013–2019
 + 0.5
(− 0.1 to + 1.0)
Poland 1990–2001 − 2.0*(− 2.4 to − 1.6) 2001–2012
 + 2.7*
(+ 2.3 to + 3.2) 2012–2019
 + 0.1
(− 0.7 to + 0.8)
Portugal 1990–1992  + 4.8*(+ 0.9 to + 8.8) 1992–2002
 + 1.0*
(+ 0.7 to + 1.4) 2002–2015
− 2.9*
(− 3.1 to − 2.7) 2015– 2019
− 0.7
(− 1.9 to + 0.5)
Romania 1990–1996  + 0.2(− 0.8 to + 1.2) 1996–2000
− 6.0*
(− 8.7 to − 3.1) 2000–2003
 + 3.9
(− 2.1 to 
+ 10.3)
2003–2019  + 0.9*(+ 0.7 to + 1.2)
Slovakia 1990–1996 − 3.4*(− 4.2 to − 2.6) 1996–1999
 + 2.5
(− 2.5 to + 7.7) 1999–2006
− 1.7*
(− 2.5 to − 0.8) 2006–2019
− 1.0*
(− 1.2 to − 0.7)
Slovenia 1990–1994
 + 14.4*
(+ 11.1 to 
+ 17.9)
1994–2003  + 1.3*(+ 0.2 to + 2.3) 2003–2009
− 11.1*
(− 13.0 to − 
9.2)
2009–2019 − 0.8*(− 1.5 to − 0.1)
Spain 1990–2006 − 1.2*(− 1.3 to − 1.1) 2006–2014
− 3.8*
(− 4.1 to − 3.4) 2014–2019
− 0.8*
(− 1.4 to − 0.1)
Sweden 1990–2006  + 1.1*(+ 1.0 to + 1.2) 2006–2014
− 2.2*
(− 2.6 to − 1.7) 2014–2019
− 0.1




(− 2.5 to − 2.2) 2003–2011
− 4.1*
(− 4.5 to − 3.8) 2011–2019
0.0
(− 0.3 to + 0.3)
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between 0 and + 0.9% have been observed. Only for females in Latvia were significant EAPC decreases identi-
fied over the time periods covered by the most recent trends (2017–2019 EAPC − 2.1%). No country displayed 
persistently negative trends for either sex.
Joinpoint analysis for T2DM disability-adjusted life-years. Sex-specific Joinpoint regression analy-
ses for T2DM DALYs between 1990 and 2019 are displayed in Fig. 4 and Supplementary Tables 3 and 4. Sig-
nificant DALY EAPCs are presented (p value < 0·05). No country demonstrated persistently negative trends. 
Persistent, significantly positive trends were observed only in Ireland for males. Notable rapid increases in DALY 
EAPCs were observed in the UK between 1996 and 1999 for males (EAPC + 5.9%) and females (EAPC + 4.8%). 
The most recent trends in the UK between (2015/16–2019) for both sexes demonstrate smaller increases in 
DALYs EAPCs to + 0.8% for males and + 0.5% for females.
Discussion
In this observational analysis of trends in the disease burden of T2DM in EU countries, we identify increasing 
prevalence of T2DM across all 28 EU countries between 1990 and 2019, with the highest relative increases in 
T2DM prevalence observed in the UK, Luxembourg and Ireland for both sexes. Over the same 30-year study 
period, mortality trends generally decreased across EU countries, however, the trends were less uniform than 
those observed for prevalence.
Being aware that the present study is observational, we are cautious to not attribute causality to the identified 
trends, however probable contributors to the increases in T2DM prevalence over the study period include ageing 
populations, increased diagnostic testing for diabetes and an increasing prevalence of  obesity12–14. The general 
reductions in T2DM mortality trends observed in this analysis are also likely contributory to the increasing 
prevalence trends.
These findings suggest that an ongoing public health target should be at primary prevention of T2DM. UK 
primary care-based screening studies have demonstrated that screening for T2DM identifies 9% of adults with 
impaired glucose regulation, which represents a state with an increased risk of T2DM and increased  mortality15,16. 
Screening for diabetes is also cost  effective17. Furthermore, evidence from Finland, the UK, the Netherlands and 
the US has demonstrated the feasibility and efficacy of T2DM prevention  programmes18–20. The Finnish Diabe-
tes Prevention Study was a randomised controlled trial with four-year follow-up conducted in Finland, which 
demonstrated a 58% reduction in the risk of T2DM in individuals with impaired glucose tolerance at the end of 
follow-up in the intervention group compared with  controls18. The intervention consisted of targeted counselling 
aimed at reducing weight, reducing fat intake and increasing physical activity. Similarly, a randomised controlled 
trial of 102 participants with impaired glucose tolerance in the UK, demonstrated an overall reduction in the 
incidence of T2DM of 55% in the intervention group (receiving targeted motivational interviewing aimed at 
weight reduction, increased physical activity and reduction of fat intake) when compared with controls over 
the 3-year study  period21. Both of the aforementioned randomised controlled trials concluded that T2DM can 
be prevented in at risk individuals by changes in lifestyle. Despite this, there appears to have been a time lag in 
the widespread translation of this evidence into clinical practice across the UK and the EU. In 2014, the NHS 
Diabetes Prevention Programme (NHS DPP) was  announced22. The programme targets adults in England at risk 
of T2DM (i.e. with non-diabetic hyperglycaemia), offering evidence-based behavioural interventions (focussed 
specifically on weight loss, diet and physical activity) in a face-to-face group setting over a minimum of 9 months’ 
duration. The NHS DPP was rolled out nationally in June 2016 and early outcomes have demonstrated favourable 
results with widespread engagement. By December 2018, 324,699 referrals to the programme had been made with 
152,294 individuals attending the initial  assessment23. Of the 17,252 individuals who had completed the assess-
ment by December 2018, a mean weight loss of 2.3 kg (95% confidence intervals 2.2–2.3 kg) and mean HbA1C 
reduction of 1.26 mmol/mol (95% confidence intervals 1.20–1.31 mmol/mol) was  identified23. The joinpoint 
analysis for T2DM prevalence performed and presented in this study demonstrates plateauing T2DM prevalence 
rates since 2015/16–2019 in the UK, with estimated annual percentage increases down to insignificant + 0.9% 
for males and 0% for females.
The high overall relative increases in prevalence observed in the UK since 1990 may in part be explained by 
the UK having the largest T2DM mortality reductions of all EU countries for males. There are numerous examples 
of how a death would be directly attributed to diabetes and registered as such within the GBD Study database: 
an example provided by the GBD collaborators is a death resulting from acute renal failure, which was caused 
by a hyperosmolar hyperglycaemic state in an individual with  T2DM24. The reductions in mortality observed in 
the UK within the present study were consistent with previous evidence derived from alternative data sources, 
including The Health Improvement Network (THIN) and the Clinical Practice Research Datalink (CPRD)25–27. 
Being cautious not to infer causality, we suggest that likely contributors to the observed reductions in mortality 
rates include the improved medical management of the disease once diagnosed, as well as earlier diagnosis and 
a resultant higher prevalence of early disease. The joinpoint regression analysis performed in the present analysis 
demonstrates recent plateaus in mortality rates from T2DM in males and females in the UK between 2011 and 
2019: explanations for these trends are lacking and should be a focus of future research.
Reducing trends in T2DM mortality were also observed in the majority of the other EU countries between 
1990 and 2019, however, trends were less uniform than those observed for prevalence. Indeed, ASMRs increased 
over the 30-year period studied in 11/28 countries for males and in 4/28 countries for females. Chen et al.28 ana-
lysed trends in all-cause mortality amongst patients with diabetes (both type 1 and type 2) using data obtained 
from 35 observational studies identified through systematic review methodology, and identified reductions in 
all cause mortality rates in the majority of Europid populations with diabetes from 2000 to 2016. The authors 
also identified that the magnitude of annual mortality reduction matched or exceeded that observed in people 
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Table 2.  Joinpoint analysis for age-standardised mortality rates (ASMRs) per 100,000 population resulting 
directly from type 2 diabetes mellitus (T2DM) in females. Italic values indicates 95% confidence intervals. 
EAPC indicates estimated annual percentage change with 95% confidence intervals in brackets. *Significantly 
different from 0 (P < 0.05).
Trend 1 Trend 2 Trend 3 Trend 4
Years EAPC Years EAPC Years EAPC Years EAPC
Austria 1990–2000 − 2.6*(− 2.9 to − 2.3) 2000–2005
 + 7.1*
(+ 5.8 to + 8.4) 2005–2012
− 4.2*
(− 4.8 to − 3.6) 2012–2019
− 1.3*
(− 1.8 to − 0.8)
Belgium 1990–1999 − 2.0*(− 2.4 to − 1.6) 1999–2009
− 3.1*
(− 3.5 to − 2.8) 2009–2016
− 4.3*
(− 5.0 to − 3.7) 2016–2019
 + 1.8
(− 0.3 to + 3.9)
Bulgaria 1990–1997  + 3.3*(+ 2.9 to + 3.8) 1997–2008
− 2.1*
(− 2.4 to − 1.9) 2008–2013
− 5.0*
(− 6.0 to − 4.0) 2013–2019
 + 1.3*
(+ 0.7 to + 1.8)
Croatia 1990–1997  + 3.3*(+ 2.0 to  + 4.7) 1997–2000
− 7.0
(− 15.8 to 
+ 2.8)
2000–2019 − 1.0*(− 1.3 to − 0.7)
Cyprus 1990–1993 − 0.9(− 3.7  to + 1.9) 1993–2012
− 4.7*
(− 4.9 to − 4.5) 2012–2019
− 2.6*




(− 11.0 to 
− 9.3)
1996–2004  + 2.4*(+ 1.7 to + 3.2) 2004–2016
 + 5.6*
(+ 5.2 to + 6.0) 2016–2019
− 3.9*
(− 6.5 to − 1.2)
Denmark 1990–1996  + 0.3(− 0.6 to + 1.1) 1996–2002
 + 5.9*
(+ 4.8 to + 7.0) 2002–2015
− 2.1*
(− 2.4 to − 1.8) 2015–2019
− 0.6
(− 2.1 to + 0.9)
Estonia 1990–1997  + 3.2*(+ 1.6 to + 4.8) 1997–2005
 + 7.9*
(+ 6.3 to + 9.6) 2005–2012
− 8.3*
(− 10.0 to 
− 6.5)
2012–2019  + 0.2(− 1.3 to + 1.7)
Finland 1990–2002 − 3.6*(− 3.9 to − 3.4) 2002–2006
− 7.0*
(− 8.8 to − 5.2) 2006–2011
− 3.9*
(− 5.1 to − 2.7) 2011–2019
 + 0.4
(0.0 to + 0.8)
France 1990–1994 − 2.0*(− 3.2 to − 0.9) 1994–2002
 + 4.2*
(+ 3.7 to + 4.7) 2002–2015
− 3.7*
(− 4.0 to − 3.5) 2015–2019
 + 0.1
(− 1.1 to + 1.2)
Germany 1990–1995 0.0(− 0.8 to + 0.8) 1995–2000
− 6.5*
(− 7.5 to − 5.4) 2000–2011
− 2.4*
(− 2.7 to − 2.2) 2011–2019
− 0.5*
(− 0.9 to − 0.1)
Greece 1990–1998 − 6.8*(− 7.4 to − 6.2) 1998–2007
 + 1.9*
(+ 1.2 to + 2.6) 2007–2014
− 3.6*
(− 4.6 to − 2.6) 2014–2019
 + 0.5
(− 0.9 to + 1.8)
Hungary 1990–1997 − 2.1*(− 3.1 to − 1.0) 1997–2006
− 2.0*
(+ 1.2 to + 2.9) 2006–2013
− 3.3*
(− 4.6 to − 2.0) 2013–2019
 + 0.2
(− 1.1 to + 1.5)
Ireland 1990–1996 − 3.4*(− 4.1 to − 2.7) 1996–2006
− 1.2*
(− 1.5 to − 0.8) 2006–2014
− 3.7*
(− 4.2 to − 3.1) 2014–2019
− 0.2
(− 1.2 to + 0.7)
Italy 1990–2006 − 2.8*(− 2.9 to − 2.6) 2006–2017
− 1.9*
(− 2.2 to − 1.7) 2017–2019
 + 1.3
(− 2.1 to + 4.8)
Latvia 1990− 1994
9.4*
(+ 5.5 to 
+ 13.5)
1994–2000 − 1.0(− 3.5 to + 1.6) 2000–2010
 + 3.8*
(+ 2.7 to + 4.9) 2010–2019
− 2.5*
(− 3.5 to − 1.4)
Lithuania 1990–1994  + 4.7*(+ 1.5 to + 8.0) 1994–2002
− 2.0*
(− 3.3 to − 0.7) 2002–2006
 + 1.9
(− 3.0 to + 7.0) 2006–2019
− 1.4*
(− 1.9 to − 0.9)
Luxembourg 1990–1993 − 0.2(− 3.0 to + 2.6) 1993–2002
− 3.6*
(− 4.2 to − 3.0) 2002–2010
− 1.0*
(− 1.7 to − 0.2) 2010–2019
− 3.1*
(− 3.6 to − 2.6)
Malta 1990–1997 − 5.4*(− 6.4 to − 4.4) 1997–2007
− 1.2*
(− 1.9 to − 0.5) 2007–2011
− 7.9*
(− 11.5 to − 
4.2)
2011–2019 − 0.9(− 1.7 – 0.0)
Netherlands 1990–1998 − 2.7*(− 3.2 to − 2.3) 1998–2002
 + 3.1*
(+ 1.0 to + 5.1) 2002–2012
− 6.7*
(− 7.0 to − 6.3) 2012–2019
− 0.1
(− 0.6 to + 0.4)
Poland 1990–2002 − 3.5*(− 3.7 to − 3.2) 2002–2013
 + 0.8*
(+ 0.5 to + 1.1) 2013–2019
− 0.8*
(− 1.5 to − 0.1)
Portugal 1990–1992  + 4.1(− 0.8 to + 9.2) 1992–2002
0.0
(− 0.4 to + 0.5) 2002–2015
− 3.7*
(− 4.0 to − 3.5) 2015–2019
− 0.1
(− 1.6 to + 1.4)
Romania 1990–1993  + 0.7(− 1.7 to + 3.1) 1993–2000
− 3.8*
(− 4.5 to − 3.0) 2000–2005
 + 1.0
(− 0.5 to + 2.5) 2005–2019
− 0.2
(− 0.4 to + 0.1)
Slovakia 1990–1996 − 4.0*(− 4.7 to − 3.4) 1996–1999
 + 1.6
(− 2.4 to + 5.8) 1999–2010
− 2.4*
(− 2.7 to − 2.1) 2010–2019
− 0.3
(− 0.7 – 0.0)
Slovenia 1990–1996  + 7.6*(+ 5.6 to + 9.7) 1996–2002
− 2.2
(− 4.6 to + 0.3) 2002–2009
− 12.2*
(− 13.9 to − 
10.5)
2009–2019 − 1.5*(− 2.4 to − 0.7)
Spain 1990–2001 − 3.3*(− 3.5 to − 3.1) 2001–2005
− 2.1*
(− 3.8 to − 0.4) 2005–2014
− 5.2*
(− 5.5 to − 4.8) 2014–2019
− 0.1
(− 0.9 to + 0.7)
Sweden 1990–1996 − 1.1*(− 1.8 to − 0.4) 1996–2004
 + 1.3*
(+ 0.8 to + 1.9) 2004–2014
− 2.0*
(− 2.3 to − 1.6) 2014–2019
 + 0.2




(− 3.8 to − 3.2) 1997–2003
− 2.0*
(− 2.4 to − 1.5) 2003–2011
− 3.6*
(− 3.9 to − 3.3) 2011–2019
 + 0.1
(− 0.1 to + 0.4)
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without diabetes in nearly 60% of populations studied which reflects well upon the evolving management of 
individuals diagnosed with diabetes. The data presented in Chen et al.’s systematic review study differs from 
that derived from the GBD study database in that they do not differentiate between type 1 and type 2 diabetes; 
they do not isolate mortality resulting directly from diabetes (and instead included all-cause mortality in indi-
viduals with diabetes), and they do not include data later than 2016. Despite these methodological differences, 
both studies identify similar trends towards the majority of Europid populations having reductions in overall 
mortality over recent decades.
To our knowledge, this is the first paper to compare T2DM prevalence, mortality and DALYs rates across EU 
countries using data obtained from the 2019 GBD Study. There are, however, several limitations which must be 
considered when appraising the results of this observational study. Firstly, there may be some inconsistencies 
both within and between countries when a cause of death is assigned. This is particularly true when considering 
chronic health conditions like T2DM, as accuracy of cause of death may be confounded by other co-morbidities. 
However, the quality of health data reporting from the EU countries and the UK is assessed and graded by the 
GBD Study as discussed in the methodology section of the manuscript, and corrections are made for under-
registration. Additionally the GBD uses garbage code redistribution algorithms to improve comparability and 
reliability (‘garbage’ codes allude to deaths attributed to poorly-defined diagnoses or conditions that cannot be 
the single underlying cause of death)3,4. Secondly, the data obtained is applicable solely for identification and 
comparison purposes of T2DM across EU countries and, as such, causal relationships cannot be drawn. Third, we 
accept that changes in coding practices (notably from ICD-9 to ICD-10), as well as changes in the WHO defini-
tion of T2DM which occurred during the observation period, may compromise the robustness of the presented 
 data29. The GBD maps deaths to causes lists as an attempt to correct for changes in coding  systems30. Finally, we 
acknowledge that confounding variables beyond the scope of discussion will have differential effects by country 
on the data presented from this observational study: using sex-specific, age-standardised mortality, prevalence 
and DALY rates attempts to account for some of the inevitably confounding variables.
Conclusion
In summary, there have been general increases in T2DM DALYs and prevalence across EU countries between 
1990 and 2019, which have been accompanied by trends towards a reduction in T2DM mortality. Public health 
measures should continue to focus on primary prevention of T2DM, given its significant costs, morbidity and 
mortality to affected populations.
Data availability
All data used in this study are freely available online at: http:// ghdx. healt hdata. org/ gbd- resul ts- tool.
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Table 3.  Joinpoint analysis for age-standardised prevalence rates (ASPRs) per 100,000 population for type 2 
diabetes (T2DM) in males. Italic values indicates 95% confidence intervals. Data presented as estimated annual 
percentage change (EAPC %), with 95% confidence intervals in brackets. P values deemed significant if < 0.05.
Trend 1 Trend 2 Trend 3 Trend 4
Years EAPC Years EAPC Years EAPC Years EAPC
Austria 1990–2003  + 3.2*(+ 3.1 to + 3.3) 2003–2009
 + 2.7*
(+ 2.5 to + 3.0) 2009–2017
 + 0.6*
(+ 0.4 to + 0.7) 2017–2019
 + 1.6*
(+ 0.4 to + 2.8)
Belgium 1990–1993  + 2.1*(+ 1.8 to + 2.3) 1993–2005
 + 1.8*
(+ 1.7 to + 1.8) 2005–2014
 + 1.6*
(+ 1.5 to + 1.6) 2014–2019
 + 2.0*
(+ 1.9 to + 2.1)
Bulgaria 1990–2000  + 2.0*(+ 2.0 to + 2.1) 2000–2005
 + 0.9*
(+ 0.6 to + 1.3) 2005–2010
 + 2.1*
(+ 1.8 to + 2.5) 2010–2019
 + 0.8*
(+ 0.7 to + 0.9)
Croatia 1990–1994  + 1.2*(+ 0.9 to + 1.6) 1994–2008
 + 1.8*
(+ 1.8 to + 1.9) 2008–2017
 + 0.4*
(+ 0.3 to + 0.5) 2017–2019
 + 4.1*
(+ 3.0 to + 5.2)
Cyprus 1990–1994  + 3.9*(+ 3.4 to + 4.4) 1994–2001
 + 0.3
(0.0 to + 0.5) 2001–2009
− 0.5*
(− 0.7 to − 0.3) 2009–2019
 + 0.1*




(+ 1.9 to + 3.1) 1994–2006
 + 1.1*
(+ 1.0 to + 1.2) 2006–2013
 + 3.5*
(+ 3.2 to + 3.9) 2013–2019
 + 2.0*
(+ 1.7 to + 2.4)
Denmark 1990–1996  + 3.1*(+ 2.9 to + 3.3) 1996–2004
 + 2.3*
(+ 2.1 to + 2.5) 2004–2011
 + 2.8*
(+ 2.6 to + 3.0) 2011–2019
 + 0.9*
(+ 0.8 to + 1.0)
Estonia 1990–2001  + 2.8*(+ 2.5 to + 3.1) 2001–2010
 + 2.0*
(+ 1.5 to + 2.5) 2010–2017
− 1.3*
(− 2.0 to − 0.6) 2017–2019
 + 2.9
(− 1.4 to + 7.5)
Finland 1990–1993 − 0.7(− 1.4 to + 0.1) 1993–1996
 + 0.3
(− 1.2 to + 1.8) 1996–2016
 + 2.1*
(+ 2.1 to + 2.2) 2016–2019
 + 3.4*
(+ 2.6 to + 4.2)
France 1990–1994  + 3.6*(+ 2.9 to + 4.4) 1994–2003
− 0.2
(− 0.4 to + 0.1) 2003–2010
 + 1.4*
(+ 1.0 to + 1.8) 2010–2019
 + 2.3*
(+ 2.1 to + 2.5)
Germany 1990–1994  + 2.4*(+ 1.6 to + 3.2) 1994–1999
 + 0.9*
(+ 0.1 to + 1.7) 1999–2007
− 0.6*
(− 0.9 to − 0.3) 2007–2019
 + 3.0*
(+ 2.9 to + 3.2)
Greece 1990–1995  + 2.0*(+ 1.9 to + 2.1) 1995–2004
 + 2.7*
(+ 2.7 to + 2.8) 2004–2014
 + 1.6*
(+ 1.5 to + 1.6) 2014–2019
 + 2.1*
(+ 1.9 to + 2.2)
Hungary 1990–1993  + 1.4(− 0.4 to + 3.1) 1993–2009
 + 2.9*
(+ 2.8 to + 3.1) 2009–2017
− 1.7*
(− 2.2 to − 1.3) 2017–2019
 + 6.0*
(+ 2.4 to + 9.7)
Ireland 1990–1995  + 2.0*(+ 1.7 to + 2.3) 1995–2007
 + 4.6*
(+ 4.5 to + 4.7) 2007–2017
 + 3.5*
(+ 3.4 to + 3.6) 2017–2019
 + 5.3*
(+ 4.0 to + 6.6)
Italy 1990–1996  + 1.2*(+ 0.3 to + 2.1) 1996–2007
 + 4.1*
(+ 3.7 to + 4.5) 2007–2015
− 2.3*
(− 2.9 to − 1.6) 2015–2019
 + 2.6*
(+ 0.9 to + 4.3)
Latvia 1990–1993  + 1.1(− 0.8 to + 2.9) 1993–2011
 + 2.4*
(+ 2.3 to + 2.6) 2011–2017
− 0.7
(− 1.5 to + 0.1) 2017–2019
 + 2.8
(− 0.9 to + 6.7)
Lithuania 1990–2011  + 1.8*(+ 1.7 to + 1.9) 2011–2017
− 1.8*
(− 2.6 to − 0.9) 2017–2019
 + 3.8
(− 0.2 to + 8.0)
Luxembourg 1990–2000  + 4.0*(+ 3.9 to + 4.1) 2000–2010
 + 6.0*
(+ 5.9 to + 6.1) 2010–2016
 + 4.6*
(+ 4.3 to + 4.9) 2016–2019
 + 1.9*
(+ 1.3 to + 2.6)
Malta 1990–1999  + 1.5*(+ 1.4 to + 1.7) 1999–2006
 + 1.8*
(+ 1.6 to + 2.0) 2006–2019
 + 0.2*
(+ 0.2 to + 0.3)
Netherlands 1990–2001  + 0.8*(+ 0.7 to + 0.9) 2001–2004
 + 1.4*
(+ 0.1 to + 2.8) 2004–2017
 + 0.9*
(+ 0.9 to + 1.0) 2017–2019
 + 1.9*
(+ 0.5 to + 3.3)
Poland 1990–1995  + 0.3*(+ 0.1 to + 0.5) 1995–2005
− 0.2*
(− 0.3 to − 0.1) 2005–2010
 + 6.0*
(+ 5.6 to + 6.3) 2010–2019
 + 1.5*
(+ 1.4 to + 1.6)
Portugal 1990–2000  + 2.1*(+ 2.0 to + 2.1) 2000–2009
 + 3.0*
(+ 2.9 to + 3.1) 2009–2015
− 1.0*
(− 1.2 to − 0.9) 2015–2019
 + 1.3*
(+ 1.1 to + 1.6)
Romania 1990–2004  + 1.4*(+ 1.4 to + 1.5) 2004–2013
 + 1.8*
(+ 1.6 to + 1.9) 2013–2017
− 0.2
(− 0.9 to + 0.4) 2017–2019
 + 4.3*
(+ 2.9 to + 5.6)
Slovakia 1990–2008  + 1.2*(+ 1.2 to + 1.2) 2008–2014
 + 1.0*
(+ 0.9 to + 1.0) 2014–2017
− 0.7*
(− 1.0 to − 0.4) 2017–2019
 + 4.3*
(+ 4.0 to + 4.7)
Slovenia 1990–2001  + 2.1*(+ 2.0 to + 2.2) 2001–2009
 + 0.3*
(+ 0.2 to + 0.5) 2009–2017
− 0.4*
(− 0.6 to − 0.3) 2017–2019
 + 4.5*
(+ 3.3 to + 5.7)
Spain 1990–1998  + 4.7*(+ 4.1 to + 5.3) 1998–2011
− 0.5*
(− 0.8 to − 0.2) 2011–2014
− 3.3
(− 7.9 to + 1.6) 2014–2019
 + 3.3*
(+ 2.1 to + 4.4)
Sweden 1990–1995  + 0.8*(+ 0.1 to + 1.4) 1995–1998
 + 3.0*
(+ 0.2 to + 6.0) 1998–2010
 + 1.8*
(+ 1.6 to + 2.0) 2010–2019
 + 1.2*




(+ 0.8 to + 1.6) 1997–2005
 + 5.0*
(+ 4.6 to + 5.4) 2005–2015
 + 3.2*
(+ 3.0 to + 3.5) 2015–2019
 + 0.9
(0.0 to + 1.8)
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Table 4.  Joinpoint analysis for age-standardised prevalence rates (ASPRs) per 100,000 population for type 
2 diabetes (T2DM) in females. Italic values indicates 95% confidence intervals. Data presented as estimated 
annual percentage change (EAPC %), with 95% confidence intervals in brackets. P values deemed significant 
if < 0.05.
Trend 1 Trend 2 Trend 3 Trend 4
Years EAPC Years EAPC Years EAPC Years EAPC
Austria 1990–2013
 + 2.1*
(+ 2.0 to + 2.1) 2013–2017
 + 0.4
(− 0.3 to + 1.2) 2017–2019
 + 3.4*
(+ 1.9 to + 4.9)
Belgium 1990–1994
 + 2.2*
(+ 1.9 to + 2.5) 1994–2003
 + 0.8*
(+ 0.7 to + 0.9) 2003–2017
 + 1.6*
(+ 1.6 to + 1.7) 2017–2019
 + 3.2*
(+ 2.3 to + 4.1)
Bulgaria 1990–2000
 + 2.1*
(+ 2.1 to + 2.2) 2000–2011
 + 0.7*
(+ 0.6 to + 0.8) 2011–2017
 + 0.9*
(+ 0.7 to + 1.1) 2017–2019
− 0.2
(− 1.0 to + 0.6)
Croatia 1990–2001
 + 1.1*
(+ 1.1 to + 1.2) 2001–2004
 + 2.2*
(+ 1.6 to + 2.8) 2004–2013
 + 0.6*
(+ 0.6 to + 0.7) 2013–2019
 + 2.0*
(+ 1.9 to + 2.1)
Cyprus 1990–1994
 + 3.4*
(+ 3.0 to + 3.7) 1994–2000
 + 0.6*
(+ 0.3 to + 0.8) 2000–2017
− 0.4*
(− 0.4 to − 0.4) 2017–2019
 + 2.5*
(+ 1.4 to + 3.5)
Czech Republic 1990–1994
 + 2.1*
(+ 1.5 to + 2.7) 1994–2001
 + 0.3
(0.0 to + 0.6) 2001–2007
 + 1.6*
(+ 1.2 to + 2.1) 2007–2019
 + 3.1*
(+ 3.0 to + 3.2)
Denmark 1990–1999
 + 3.2*
(+ 3.0 to + 3.3) 1999–2005
 + 0.8*
(+ 0.5 to + 1.2) 2005–2012
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